$ONMD
OneMedNet Corp

2024 Q3 Form 10-Q Financial Statement

#000149315224050454 Filed on December 17, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2023 Q3
Revenue $142.0K $680.0K
YoY Change -79.12%
Cost Of Revenue $226.0K $293.0K
YoY Change -22.87%
Gross Profit -$84.00K $33.00K
YoY Change -354.55%
Gross Profit Margin -59.15% 4.85%
Selling, General & Admin $2.005M $2.890M
YoY Change -30.62% 5373.48%
% of Gross Profit 8757.58%
Research & Development $298.0K $405.0K
YoY Change -26.42%
% of Gross Profit 1227.27%
Depreciation & Amortization $20.00K
YoY Change
% of Gross Profit 60.61%
Operating Expenses $2.303M $4.450M
YoY Change -48.25% 755.72%
Operating Profit -$2.387M -$1.927M
YoY Change 23.87% 270.56%
Interest Expense $14.00K -$1.170M
YoY Change -101.2% -299.22%
% of Operating Profit
Other Income/Expense, Net $329.0K -$40.00K
YoY Change -922.5% -64.86%
Pretax Income -$4.990M
YoY Change 10619.43%
Income Tax
% Of Pretax Income
Net Earnings -$2.100M -$1.691M
YoY Change 24.21% 1003.01%
Net Earnings / Revenue -1478.87% -248.62%
Basic Earnings Per Share -$0.07 -$3.23
Diluted Earnings Per Share -$0.07 -$1.08
COMMON SHARES
Basic Shares Outstanding 27.88M shares 4.281M shares
Diluted Shares Outstanding 27.88M shares 4.281M shares

Balance Sheet

Concept 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $600.0K
YoY Change 155.41%
Cash & Equivalents $1.900M $611.8K
Short-Term Investments
Other Short-Term Assets $100.0K
YoY Change
Inventory
Prepaid Expenses
Receivables $63.00K $86.39K
Other Receivables $2.060M
Total Short-Term Assets $4.304M $2.846M
YoY Change 51.25% 1111.28%
LONG-TERM ASSETS
Property, Plant & Equipment $84.00K $92.37K
YoY Change -9.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $84.00K $92.37K
YoY Change -9.06% -99.92%
TOTAL ASSETS
Total Short-Term Assets $4.304M $2.846M
Total Long-Term Assets $84.00K $92.37K
Total Assets $4.388M $2.938M
YoY Change 49.36% -97.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.500M
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $2.306M $12.40M
YoY Change -81.4% 107726.09%
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $18.63M $14.28M
YoY Change 30.46% 882.47%
LONG-TERM LIABILITIES
Long-Term Debt $2.200M
YoY Change -15.38%
Other Long-Term Liabilities $28.00K $1.200M
YoY Change -97.67% -74.1%
Total Long-Term Liabilities $28.00K $3.400M
YoY Change -99.18% -52.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.63M $14.28M
Total Long-Term Liabilities $28.00K $3.400M
Total Liabilities $18.66M $17.68M
YoY Change 5.54% 103.5%
SHAREHOLDERS EQUITY
Retained Earnings -$99.20M -$36.83M
YoY Change 169.31% 335.84%
Common Stock $2.000K $455.00
YoY Change 339.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$14.27M -$14.74M
YoY Change
Total Liabilities & Shareholders Equity $4.388M $2.938M
YoY Change 49.36% -97.56%

Cashflow Statement

Concept 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.100M -$1.691M
YoY Change 24.21% 1003.01%
Depreciation, Depletion And Amortization $20.00K
YoY Change
Cash From Operating Activities -$4.060M
YoY Change 1057.12%
INVESTING ACTIVITIES
Capital Expenditures $30.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $250.0K
YoY Change -128.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.180M
YoY Change 186.01%
NET CHANGE
Cash From Operating Activities -4.060M
Cash From Investing Activities 250.0K
Cash From Financing Activities 4.180M
Net Change In Cash 370.0K
YoY Change 62.68%
FREE CASH FLOW
Cash From Operating Activities -$4.060M
Capital Expenditures $30.00K
Free Cash Flow -$4.090M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001849380
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1934000 usd
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28175172 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27987427 shares
ONMD Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
63000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
151000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4304000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
84000 usd
CY2024Q3 us-gaap Assets
Assets
4388000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6161000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
428000 usd
ONMD Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
-17872000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11913000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-816000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26299000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2058000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13840000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7755000 usd
us-gaap Net Income Loss
NetIncomeLoss
-31284000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.56
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27878399 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27878399 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4280777 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4280777 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25051293 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25051293 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4139730 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4139730 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13442000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
242000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
137000 usd
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
529000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-15701000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
103000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3589000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-19187000 usd
CY2023Q4 us-gaap Crypto Asset Fair Value
CryptoAssetFairValue
usd
CY2023Q4 ONMD Yorkville Notes Payable Current
YorkvilleNotesPayableCurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2023Q3 ONMD Fair Value Adjustment Of Private Investment In Public Equity
FairValueAdjustmentOfPrivateInvestmentInPublicEquity
usd
ONMD Fair Value Adjustment Of Private Investment In Public Equity
FairValueAdjustmentOfPrivateInvestmentInPublicEquity
usd
CY2023Q3 ONMD Gain Loss On Fair Value Of Yorkville Note
GainLossOnFairValueOfYorkvilleNote
usd
ONMD Gain Loss On Fair Value Of Yorkville Note
GainLossOnFairValueOfYorkvilleNote
usd
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
usd
CY2023Q3 us-gaap Crypto Asset Realized And Unrealized Gain Loss Nonoperating
CryptoAssetRealizedAndUnrealizedGainLossNonoperating
usd
us-gaap Crypto Asset Realized And Unrealized Gain Loss Nonoperating
CryptoAssetRealizedAndUnrealizedGainLossNonoperating
usd
CY2024Q3 ONMD Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
usd
CY2024Q3 ONMD Stock Warrant Expense Non Operating
StockWarrantExpenseNonOperating
usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
ONMD Fair Value Adjustment Of Private Investment In Public Equity
FairValueAdjustmentOfPrivateInvestmentInPublicEquity
usd
ONMD Change In Fair Value Of Yorkville Note
ChangeInFairValueOfYorkvilleNote
usd
us-gaap Crypto Asset Realized And Unrealized Gain Loss Nonoperating
CryptoAssetRealizedAndUnrealizedGainLossNonoperating
usd
us-gaap Crypto Asset Realized Loss Nonoperating
CryptoAssetRealizedLossNonoperating
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
ONMD Noncash Interest
NoncashInterest
usd
ONMD Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
usd
us-gaap Payment For Acquisition Crypto Asset
PaymentForAcquisitionCryptoAsset
usd
us-gaap Proceeds From Disposal Crypto Asset
ProceedsFromDisposalCryptoAsset
usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
usd
ONMD Repayment For Common Stock Repurchase
RepaymentForCommonStockRepurchase
usd
ONMD Repayment Of Deferred Underwriter Fees
RepaymentOfDeferredUnderwriterFees
usd
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
ONMD Business Combination Costs
BusinessCombinationCosts
usd
ONMD Issuance Of Common Stock To Settle Deferred Underwriter Fee Payable
IssuanceOfCommonStockToSettleDeferredUnderwriterFeePayable
usd
ONMD Consideration For Repurchase Of Common Stock Included In Accounts Payable And Accrued Expenses
ConsiderationForRepurchaseOfCommonStockIncludedInAccountsPayableAndAccruedExpenses
usd
CY2023Q4 us-gaap Crypto Asset Fair Value
CryptoAssetFairValue
usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40386
dei Entity Registrant Name
EntityRegistrantName
ONEMEDNET CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2076743
dei Entity Address Address Line1
EntityAddressAddressLine1
6385 Old Shady Oak Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
Eden Prairie
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55344
dei City Area Code
CityAreaCode
(800)
dei Local Phone Number
LocalPhoneNumber
918-7189
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27987427 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47000 usd
CY2024Q3 us-gaap Crypto Asset Fair Value
CryptoAssetFairValue
2156000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
152000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
166000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
365000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
99000 usd
CY2023Q4 us-gaap Assets
Assets
464000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4965000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
254000 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
2992000 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
2992000 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1593000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1637000 usd
CY2024Q3 ONMD Yorkville Notes Payable Current
YorkvilleNotesPayableCurrent
1911000 usd
CY2024Q3 ONMD Deferred Underwriter Fee Payable Current
DeferredUnderwriterFeePayableCurrent
3237000 usd
CY2023Q4 ONMD Deferred Underwriter Fee Payable Current
DeferredUnderwriterFeePayableCurrent
3525000 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
2306000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
465000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18628000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13838000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
68000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
18656000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
13906000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23572232 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23572232 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
85455000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
77996000 usd
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
187745 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
529000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99196000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91440000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-14268000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13442000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4388000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
464000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
142000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
326000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
617000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
681000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
226000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
293000 usd
us-gaap Cost Of Revenue
CostOfRevenue
872000 usd
us-gaap Cost Of Revenue
CostOfRevenue
812000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
-84000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
33000 usd
us-gaap Gross Profit
GrossProfit
-255000 usd
us-gaap Gross Profit
GrossProfit
-131000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1865000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1312000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4934000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2475000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
140000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
243000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
623000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
813000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
298000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
405000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1127000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1566000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2303000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1960000 usd
us-gaap Operating Expenses
OperatingExpenses
6684000 usd
us-gaap Operating Expenses
OperatingExpenses
4854000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2387000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1927000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6939000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4985000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
36000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
120000 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5000 usd
CY2024Q3 ONMD Fair Value Adjustment Of Private Investment In Public Equity
FairValueAdjustmentOfPrivateInvestmentInPublicEquity
-77000 usd
ONMD Fair Value Adjustment Of Private Investment In Public Equity
FairValueAdjustmentOfPrivateInvestmentInPublicEquity
-44000 usd
CY2024Q3 ONMD Gain Loss On Fair Value Of Yorkville Note
GainLossOnFairValueOfYorkvilleNote
-262000 usd
ONMD Gain Loss On Fair Value Of Yorkville Note
GainLossOnFairValueOfYorkvilleNote
561000 usd
CY2024Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
160000 usd
CY2024Q3 us-gaap Crypto Asset Realized And Unrealized Gain Loss Nonoperating
CryptoAssetRealizedAndUnrealizedGainLossNonoperating
-124000 usd
us-gaap Crypto Asset Realized And Unrealized Gain Loss Nonoperating
CryptoAssetRealizedAndUnrealizedGainLossNonoperating
-124000 usd
CY2023Q3 ONMD Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
-7621000 usd
CY2023Q3 ONMD Stock Warrant Expense Non Operating
StockWarrantExpenseNonOperating
4285000 usd
ONMD Stock Warrant Expense Non Operating
StockWarrantExpenseNonOperating
33000 usd
ONMD Stock Warrant Expense Non Operating
StockWarrantExpenseNonOperating
8385000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
329000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.23
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2109000 usd
CY2024Q3 ONMD Stock Issued During Period Value Issuance Of Common Stock And Prefunded Warrants In Connection With Private Placements Net Of Issuance Costs
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsInConnectionWithPrivatePlacementsNetOfIssuanceCosts
6270000 usd
CY2024Q3 ONMD Stock Issued During Period Value Issuance Of Common Stock To Settle Commitment Fee
StockIssuedDuringPeriodValueIssuanceOfCommonStockToSettleCommitmentFee
500000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
207000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2058000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-14268000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-26359000 usd
CY2023Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1935000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
368000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7843000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-31899000 usd
CY2023Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
2165000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
280000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9601000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-39055000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-39055000 usd
CY2023Q3 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
4285000 usd
CY2023Q3 ONMD Stock Issued During Period Value Issuance Of Legacy Series A Two Preferred Stock
StockIssuedDuringPeriodValueIssuanceOfLegacySeriesATwoPreferredStock
16000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
798000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13840000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-47796000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-47796000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7755000 usd
us-gaap Net Income Loss
NetIncomeLoss
-31284000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
31000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
447000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1446000 usd
ONMD Stock Warrant Expense
StockWarrantExpense
33000 usd
ONMD Stock Warrant Expense
StockWarrantExpense
8385000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5000 usd
ONMD Fair Value Adjustment Of Private Investment In Public Equity
FairValueAdjustmentOfPrivateInvestmentInPublicEquity
-44000 usd
ONMD Change In Fair Value Of Yorkville Note
ChangeInFairValueOfYorkvilleNote
-561000 usd
us-gaap Crypto Asset Realized And Unrealized Gain Loss Nonoperating
CryptoAssetRealizedAndUnrealizedGainLossNonoperating
-124000 usd
us-gaap Crypto Asset Realized Loss Nonoperating
CryptoAssetRealizedLossNonoperating
51000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15000 usd
ONMD Noncash Interest
NoncashInterest
96000 usd
ONMD Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
17872000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-89000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
86000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-15000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-14000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1232000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
340000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
174000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
228000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4956000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3066000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000 usd
us-gaap Payment For Acquisition Crypto Asset
PaymentForAcquisitionCryptoAsset
2800000 usd
us-gaap Proceeds From Disposal Crypto Asset
ProceedsFromDisposalCryptoAsset
469000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2347000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6270000 usd
ONMD Proceeds From Issuance Of Shareholder Loans
ProceedsFromIssuanceOfShareholderLoans
2000000 usd
ONMD Proceeds From Issuance Of Shareholder Loans
ProceedsFromIssuanceOfShareholderLoans
704000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1350000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
500000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
200000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000 usd
ONMD Repayment For Common Stock Repurchase
RepaymentForCommonStockRepurchase
100000 usd
ONMD Repayment Of Deferred Underwriter Fees
RepaymentOfDeferredUnderwriterFees
100000 usd
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
30000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3875000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
16000 usd
ONMD Business Combination Costs
BusinessCombinationCosts
1160000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9190000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3435000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1887000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
341000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
271000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1934000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
612000 usd
ONMD Issuance Of Common Stock To Settle Deferred Underwriter Fee Payable
IssuanceOfCommonStockToSettleDeferredUnderwriterFeePayable
242000 usd
ONMD Consideration For Repurchase Of Common Stock Included In Accounts Payable And Accrued Expenses
ConsiderationForRepurchaseOfCommonStockIncludedInAccountsPayableAndAccruedExpenses
-429000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2100000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7800000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99200000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1900000 usd
CY2024Q3 ONMD Crypto Cash
CryptoCash
2200000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Crypto Asset Number Of Units
CryptoAssetNumberOfUnits
34000 integer
CY2024Q3 us-gaap Crypto Asset Cost
CryptoAssetCost
2280000 usd
CY2024Q3 us-gaap Crypto Asset Fair Value
CryptoAssetFairValue
2156000 usd
us-gaap Crypto Asset Addition
CryptoAssetAddition
2800000 usd
us-gaap Crypto Asset Disposition
CryptoAssetDisposition
520000 usd
us-gaap Crypto Asset Realized And Unrealized Gain Loss Nonoperating
CryptoAssetRealizedAndUnrealizedGainLossNonoperating
-124000 usd
CY2024Q3 us-gaap Crypto Asset Fair Value
CryptoAssetFairValue
2156000 usd
CY2024Q3 us-gaap Crypto Asset Disposition
CryptoAssetDisposition
500000 usd
us-gaap Crypto Asset Disposition
CryptoAssetDisposition
500000 usd
CY2024Q3 us-gaap Crypto Asset Realized And Unrealized Loss Nonoperating
CryptoAssetRealizedAndUnrealizedLossNonoperating
51000 usd
us-gaap Crypto Asset Realized And Unrealized Loss Nonoperating
CryptoAssetRealizedAndUnrealizedLossNonoperating
51000 usd
CY2024Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4500000 usd
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
50000 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
50000 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
ONMD Stock Warrant Expense
StockWarrantExpense
33000 usd
CY2024Q3 ONMD Yorkville Notes Payable Current
YorkvilleNotesPayableCurrent
1900000 usd
CY2023Q4 us-gaap Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method
BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod
the Company was obligated to compensate EF Hutton at a new share price equal to the difference in amount on such date. Due to the decrease in share value on the six-month anniversary, the Company was required to either pay to EF Hutton an additional $2.8 million or issue to EF Hutton an additional 3,175,000 shares of Common Stock.
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
277778 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
200000 usd
us-gaap Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method
BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod
the Company was obligated to pay to EF Hutton the true-up of either $2.8 million or 3,175,000 shares of Common Stock valued at $0.88 per share, plus the $0.5 million promissory note. Upon the occurrence of an event of default, the promissory note bears interest at a rate of 12.5% until such event of default is cured.
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2024-03-01
CY2024Q3 us-gaap Interest Expense
InterestExpense
14000 usd
us-gaap Interest Expense
InterestExpense
55000 usd
CY2024Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
100000 usd
CY2024Q2 ONMD Stockholders Deficit Description
StockholdersDeficitDescription
An Advance may not exceed the greater of (i) 100% of the average of the daily trading volume of the Common Stock on Nasdaq, during the five consecutive trading days immediately preceding the date of the Advance, and (ii) five hundred thousand (500,000) shares of Common Stock.
CY2024Q2 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
500000 usd
CY2024Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Net
EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
200000 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14951799 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15102501 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
207000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
798000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
447000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1446000 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14380958 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12181019 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14380958 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12181019 shares
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2156000 usd
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
3532000 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1660000 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
400000 usd
CY2024Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
100000 usd
CY2024Q2 us-gaap Other Long Term Debt
OtherLongTermDebt
100000 usd
CY2024Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.080 pure
us-gaap Debt Instrument Term
DebtInstrumentTerm
P1Y
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
654000 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
454000 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1600000 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
52000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
11000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
2306000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
465000 usd
CY2024Q3 us-gaap Share Price
SharePrice
10.00
us-gaap Lease Cost
LeaseCost
530 usd
CY2024Q3 us-gaap Payments For Rent
PaymentsForRent
2000 usd
CY2023Q3 us-gaap Payments For Rent
PaymentsForRent
2000 usd
us-gaap Payments For Rent
PaymentsForRent
6000 usd
us-gaap Payments For Rent
PaymentsForRent
6000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-050454-index-headers.html Edgar Link pending
0001493152-24-050454-index.html Edgar Link pending
0001493152-24-050454.txt Edgar Link pending
0001493152-24-050454-xbrl.zip Edgar Link pending
ex10-8.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
onmd-20240930.xsd Edgar Link pending
onmd-20240930_cal.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
onmd-20240930_def.xml Edgar Link unprocessable
onmd-20240930_lab.xml Edgar Link unprocessable
onmd-20240930_pre.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending